Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.34 |
| ▸ | EPAS1 | Q99814 | 6/20 | 0.34 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | HRH2 | P25021 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20037565 | 1.00 | CYP2D6 (0.37) | CYP2D6CYP2C19ALDH1A1DRD2DRD3 | |
| SCHEMBL20255404 | 0.92 | CYP2D6 (0.37) | CYP2D6CYP2C19DRD2DRD3DRD4 | |
| SCHEMBL20255403 | 0.92 | CYP2D6 (0.37) | CYP2D6CYP2C19DRD2DRD3DRD4 | |
| SCHEMBL20037567 | 0.85 | HRH3 (0.41) | ALDH1A1 | |
| SCHEMBL18291438 | 0.80 | MAPK1 (0.43) | CYP2D6CYP2C19ALDH1A1DRD2DRD3 | |
| SCHEMBL20203571 | 0.76 | ALDH1A1 (0.45) | ALDH1A1DRD2DRD3DRD4 | |
| SCHEMBL20203572 | 0.76 | ALDH1A1 (0.45) | ALDH1A1DRD2DRD3DRD4 | |
| SCHEMBL20037575 | 0.75 | MCHR1 (0.36) | DRD2DRD3DRD4 | |
| SCHEMBL28055262 | 0.74 | DRD2 (0.40) | CYP2D6CYP2C19ALDH1A1DRD2DRD3 | |
| SCHEMBL28055260 | 0.74 | DRD2 (0.40) | CYP2D6CYP2C19ALDH1A1DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| EP-3305785-A1 | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Teijin Pharma Limited (JP) | 2018-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | CYP2D6 70/4885CYP2C19 518/4885ALDH1A1 944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.